Skip to content

School Screening and Telemedicine Specialty Referral to Address Childhood Hearing Loss in Rural Alaska

North STAR Trial: Specialty Telemedicine Access for Referrals (STAR) in Rural Alaska

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05593484
Enrollment
8060
Registered
2022-10-25
Start date
2023-09-01
Completion date
2027-06-30
Last updated
2026-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hearing Loss

Keywords

Rural, Hearing loss, Telemedicine, Telehealth, School, Disparities, Screening

Brief summary

The prevalence of childhood hearing loss in rural Alaska is disproportionately high and predominately infection-related. With preventive screenings and access to health care, much of childhood hearing loss is preventable. Although state-mandated school screening helps identify children with hearing loss, loss to follow-up is pervasive and exacerbated by a scarcity of specialists in rural regions. A mixed methods cluster randomized trial conducted in northwest Alaska demonstrated that telemedicine can significantly reduce loss to follow-up. This stepped wedge trial, in partnership with Southcentral Foundation, will build on this existing work to develop a model that can be scaled in diverse environments. We will adapt and implement a new telemedicine intervention called Specialty Telemedicine Access for Referrals (STAR). This trial will be conducted in 3 regions in rural Alaska that represent multiple healthcare systems. Based on stakeholder feedback and evidence generated from the previous trial, an enhanced mobile health (mHealth) hearing screening will be implemented in all participating schools prior to the STAR intervention, and the telemedicine referral to specialty care (STAR intervention) will be moved from the clinic directly into the school. This stepped-wedge cluster randomized trial is part of a larger hybrid type 1 effectiveness-implementation trial. The stepped wedge trial will evaluate the effectiveness of the STAR intervention in reducing loss to follow-up from referred school hearing screening in 3 regions of Alaska: Kodiak, Petersburg and Lower Yukon (n=23 schools, \ 2,015 K-12 students/year). The STAR Intervention will be compared to the standard referral of a letter home to families. Cluster randomization at the level of school will be performed, with schools (clusters) randomized to one of two sequences. The effectiveness outcome (i.e., proportion of children who receive follow-up) will be evaluated over three academic years (2023-2026), with STAR rolled out in a stepwise manner for each of the two sequences (academic year 2024-2025 for sequence 1 and academic year 2025-2026 for sequence 2). The control periods for each sequence will be academic year 2023-2024 for sequence 1 and academic years 2023-2024 and 2024-2025 for sequence 2. Enhanced screening will be rolled out to both sequences at the same time (i.e., non-randomized) beginning academic year 2023-2024. An implementation evaluation will be conducted to refine and adapt the enhanced hearing screening and STAR intervention throughout the trial. Implementation data will be collected starting academic year 2022-2023 and then annually for each of the subsequent years. Timeline update: Based on feedback from community partners, we extended the trial for one year to allow for community-informed adaptations of the enhanced screening. Now the STAR intervention will be rolled out in 2025-2026 for sequence 1 and 2026-2027 for sequence 2.

Interventions

Schools in the control condition will use standard referral, as determined by the school district. Standard referral is typically a letter home from the school to parents/caregivers of children who refer screening.

OTHERSpecialty Telemedicine Access for Referrals (STAR)

The STAR intervention will include a lay-friendly smartphone or tablet that connects to tools necessary for an ear and hearing evaluation. If a child requires referral from hearing screening, a school nurse/teacher will complete the established protocol for the STAR intervention and send the information asynchronously to an audiologist for review.

Sponsors

University of Arkansas
Lead SponsorOTHER
Southcentral Foundation
CollaboratorOTHER
Duke University
CollaboratorOTHER
National Institute on Deafness and Other Communication Disorders (NIDCD)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Outcomes Assessor)

Masking description

Statisticians will also be masked to group allocation until analysis is complete.

Intervention model description

Approximately 23 schools from 3 regions are participating in the effectiveness trial. Clusters (\ 23 schools) will be randomized to one of two sequences. In academic year 2023-2024, all schools will receive enhanced screening (with standard referral). The Specialty Telemedicine Access for Referrals (STAR) intervention will be rolled out in a stepwise manner in academic years 2024-2025 and 2025-2026 depending on sequence randomization. Timeline update: Due to feedback from community partners, we extended the trial for one year. In academic year 2024-2025 all schools received the adapted enhanced screening. The STAR intervention will be rolled out in 2025-2026 and 2026-2027 depending on sequence randomization.

Eligibility

Sex/Gender
ALL
Age
3 Years to 21 Years
Healthy volunteers
Yes

Inclusion criteria

* Enrolled in one of the participating schools in the 3 regions * Children from grades (K-12) that are typically screened within participating schools * Eligible regardless of age, gender, race, or ethnicity

Exclusion criteria

N/A

Design outcomes

Primary

MeasureTime frameDescription
Proportion of children who receive follow-upProportion of children who receive follow-up will be measured by the occurrence of an ear/hearing encounter, up to 60 days from the date of screening.This outcome will be measured each school year, for 4 years, based on the updated timeline.

Countries

United States

Contacts

CONTACTSusan Emmett, MD, MPH
sdemmett@uams.edu5016031212
CONTACTSamantha Robler, Aud, PhD
skrobler@uams.edu907-434-0433
PRINCIPAL_INVESTIGATORMatthew Hirschfeld, MD,PhD

Vice President-Specialty Services, Southcentral Foundation, Alaska Native Medical Center

PRINCIPAL_INVESTIGATORSusan Emmett, MD, MPH

University of Arkansas Medical Sciences

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 7, 2026